PURPOSE: (18)F-fluorodeoxyglucose (FDG) PET is a non-invasive imaging technique recommended for the management of both diffuse large B-cell and Hodgkin's lymphomas. This retrospective study investigated the value of FDG PET for initial staging and its prognostic impact on patients with mantle cell lymphoma (MCL). METHODS: A total of 44 untreated MCL patients assessed by both conventional evaluations (CE) and FDG PET for initial staging were included. The maximum standardized uptake value (SUV(max)) in the most intense pathological area was recorded for each patient. Disease status after chemotherapy completion was assessed according to the International Workshop Criteria (IWC) for non-Hodgkin's lymphoma (NHL) response and IWC+PET. RESULTS: FDG PET uptakes at diagnosis were abnormal in all cases. Compared to CT scan, nodal and extranodal sites were only detected by FDG PET. Due to insufficient sensibility for bone marrow (BM) and gastrointestinal (GI) involvement, FDG PET did not modify initial staging. Positive and negative predictive values of IWC+PET for relapse at 1 year were 62.5 and 100%. With a median follow-up of 21 months, only the International Prognostic Index (IPI) and IWC+PET modified both event-free survival (EFS) (p = .02 and .0001, respectively) and overall survival (p = .03 and .05, respectively) duration. When combining IPI and SUV(max) at diagnosis, we were able to identify patients with low (29%; no relapse/progression), intermediate (42%; median EFS: 37 months) and high risk (29%, median EFS: 22 months) (p = .004). CONCLUSION: In MCL, FDG PET at diagnosis is complementary to CE, but BM and GI biopsies remain mandatory. IWC+PET criteria are highly efficient to identify patients with high risk for early relapse. Combining IPI and SUV(max) may predict patient outcome and warrant further prospective investigations towards designing risk-adapted strategies.
PURPOSE: (18)F-fluorodeoxyglucose (FDG) PET is a non-invasive imaging technique recommended for the management of both diffuse large B-cell and Hodgkin's lymphomas. This retrospective study investigated the value of FDG PET for initial staging and its prognostic impact on patients with mantle cell lymphoma (MCL). METHODS: A total of 44 untreated MCLpatients assessed by both conventional evaluations (CE) and FDG PET for initial staging were included. The maximum standardized uptake value (SUV(max)) in the most intense pathological area was recorded for each patient. Disease status after chemotherapy completion was assessed according to the International Workshop Criteria (IWC) for non-Hodgkin's lymphoma (NHL) response and IWC+PET. RESULTS:FDG PET uptakes at diagnosis were abnormal in all cases. Compared to CT scan, nodal and extranodal sites were only detected by FDG PET. Due to insufficient sensibility for bone marrow (BM) and gastrointestinal (GI) involvement, FDG PET did not modify initial staging. Positive and negative predictive values of IWC+PET for relapse at 1 year were 62.5 and 100%. With a median follow-up of 21 months, only the International Prognostic Index (IPI) and IWC+PET modified both event-free survival (EFS) (p = .02 and .0001, respectively) and overall survival (p = .03 and .05, respectively) duration. When combining IPI and SUV(max) at diagnosis, we were able to identify patients with low (29%; no relapse/progression), intermediate (42%; median EFS: 37 months) and high risk (29%, median EFS: 22 months) (p = .004). CONCLUSION: In MCL, FDG PET at diagnosis is complementary to CE, but BM and GI biopsies remain mandatory. IWC+PET criteria are highly efficient to identify patients with high risk for early relapse. Combining IPI and SUV(max) may predict patient outcome and warrant further prospective investigations towards designing risk-adapted strategies.
Authors: B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos Journal: J Clin Oncol Date: 1999-04 Impact factor: 44.544
Authors: Christiane Pott; Carsten Schrader; Stefan Gesk; Lana Harder; Markus Tiemann; Thorsten Raff; Monika Brüggemann; Matthias Ritgen; Benedikt Gahn; Michael Unterhalt; Martin Dreyling; Wolfgang Hiddemann; Reiner Siebert; Peter Dreger; Michael Kneba Journal: Blood Date: 2005-12-06 Impact factor: 22.113
Authors: Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl Journal: J Clin Oncol Date: 2007-01-22 Impact factor: 44.544
Authors: Olaf Determann; Eva Hoster; German Ott; Heinz Wolfram Bernd; Christoph Loddenkemper; Martin Leo Hansmann; Thomas E F Barth; Michael Unterhalt; Wolfgang Hiddemann; Martin Dreyling; Wolfram Klapper Journal: Blood Date: 2007-12-12 Impact factor: 22.113
Authors: Lieselot Brepoels; Sigrid Stroobants; Walter De Wever; Daan Dierickx; Peter Vandenberghe; Jose Thomas; Luc Mortelmans; Gregor Verhoef; Christiane De Wolf-Peeters Journal: Leuk Lymphoma Date: 2008-09
Authors: Maroun Karam; Ashar Ata; Kevin Irish; Paul J Feustel; Felix M Mottaghy; Sigrid G Stroobants; Gregor E Verhoef; Surya Chundru; Vonda Douglas-Nikitin; Ching-yee Oliver Wong; Lieselot M Brepoels Journal: Nucl Med Commun Date: 2009-10 Impact factor: 1.690
Authors: Saar Gill; Max Wolf; H Miles Prince; Henry Januszewicz; David Ritchie; Rodney J Hicks; John F Seymour Journal: Clin Lymphoma Myeloma Date: 2008-06
Authors: Stephen E Spurgeon; Brian G Till; Peter Martin; Andre H Goy; Martin P Dreyling; Ajay K Gopal; Michael LeBlanc; John P Leonard; Jonathan W Friedberg; Lawrence Baizer; Richard F Little; Brad S Kahl; Mitchell R Smith Journal: J Natl Cancer Inst Date: 2016-12-31 Impact factor: 13.506
Authors: Arne Kolstad; Anna Laurell; Mats Jerkeman; Kirsten Grønbæk; Erkki Elonen; Riikka Räty; Lone Bredo Pedersen; Annika Loft; Trond Velde Bogsrud; Eva Kimby; Per Boye Hansen; Unn-Merete Fagerli; Herman Nilsson-Ehle; Grete Fossum Lauritzsen; Anne Kristine Lehmann; Christer Sundstrom; Marja-Liisa Karjalainen-Lindsberg; Elisabeth Ralfkiaer; Mats Ehinger; Jan Delabie; Hans Bentzen; Jukka Schildt; Kamelia Kostova-Aherdan; Henrik Frederiksen; Peter de Nully Brown; Christian H Geisler Journal: Blood Date: 2014-03-20 Impact factor: 22.113